• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Healthcare·DEVA.IS
Share

Deva Holding A.S. Stocks

TRY 71.55Last Updated 13.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

TRY 301.00M

TRY 71.55
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Deva Holding A.S. is a Turkish pharmaceutical firm specializing in the development and distribution of a wide array of medicinal goods. Its extensive portfolio encompasses treatments for various conditions, including cancer (antineoplastic agents), immune system disorders (immunomodulating agents), skin ailments (dermatological products), hormonal imbalances (systemic hormonal preparations), and infectious or parasitic diseases (anti-infective and antiparasitic products for systemic use). Additionally, the company offers dietary supplements and electrolyte solutions. Deva Holding also supplies pharmaceuticals targeting major bodily systems such as the urogenital and reproductive systems, blood and hematopoietic organs, the cardiovascular system, musculoskeletal system, nervous system, digestive tract and metabolism, respiratory system, and sensory organs. Furthermore, its offerings include specific drug classes like cephalosporins and penicillin, inhalation therapies, both solid and liquid oncological preparations, and veterinary pharmaceuticals. It also produces active pharmaceutical ingredients (APIs), various sterile dosage forms such as ampoules, liquid and lyophilized vials, and ophthalmic drops, alongside medical ampoules for sterile injectables; cologne is also part of its product line. Beyond its domestic operations, Deva Holding exports its products to approximately 60 nations globally. Established in 1958, the company maintains its headquarters in Istanbul, Turkey, and operates as a subsidiary of Eastpharma S.à R.L.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA, undervalued on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.07.2026 08:30

Disney's decision to abandon streaming will boost its stock by 40% — Wells Fargo

14.07.2026 07:30

Jefferies recommended buying shares of Hoka's parent company. The brand could replicate UGG's success.

14.07.2026 02:42

Prosecutors from 12 U.S. states have filed a lawsuit against the Paramount-Warner Bros. Discovery deal

14.07.2026 01:22

SK Hynix Led the Decline Among Chipmakers; Oil Prices Suffered Their Sharpest One-Day Drop Since 2020

14.07.2026 00:44

Oil prices jumped by nearly 10%. The price of Brent crude exceeded $83 per barrel

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026